NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, has announced a new partnership with Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, to support biotech startups by providing needed resources such as product and applications expertise and its networks to advance startup research and development (R&D).

Since 2019, NSG BioLabs has been assisting innovators in creating impactful solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other impactful areas. With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with local and international partners, suppliers, and industry experts, NSG BioLabs has helped over 40 companies as residents.

The company's residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones. The startup residents alone have successfully raised nearly $400 million in funding and supported hundreds of jobs.

"Empowering innovative biotech startups is of strategic importance to the Eppendorf Group, as they drive the future of medical innovation and the development of new treatments. Being part of this scientific community is crucial and this collaboration will be the catalyst for transformative breakthroughs in Singapore and beyond," said Surendran Krishnamurthi, Managing Director Eppendorf Southeast Asia.